Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in J Infect

Retrieve available abstracts of 56 articles:
HTML format

Single Articles

    November 2021
  1. LEBOURGEOIS S, Menidjel R, Chenane HR, Ferre VM, et al
    Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00556.

  2. GIMENEZ E, Alberola J, Torres I, Albert E, et al
    Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2021 Nov 2. pii: S0163-4453(21)00542.

    October 2021
  3. CHONG Y, Tani N, Goto T, Yonekawa A, et al
    Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00508.

  4. GUPTA A, Bhoyar RC, Mirza S, Jolly B, et al
    SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.
    J Infect. 2021 Oct 19. pii: S0163-4453(21)00506.

  5. ANIS E, Haas EJ, Indenbaum V, Singer SR, et al
    A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19.
    J Infect. 2021 Oct 6. pii: S0163-4453(21)00497.
    PubMed     Abstract available

    September 2021
  6. FERRE VM, Lebourgeois S, Menidjel R, Collin G, et al
    Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00488.

  7. LUNA-MUSCHI A, Borges IC, de Faria E, Barboza AS, et al
    Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers.
    J Infect. 2021 Sep 16. pii: S0163-4453(21)00474.

    August 2021
  8. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected.
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00433.
    PubMed     Abstract available

  9. WEISSMAN YL, Cooper L, Sternbach N, Ashkenazi-Hoffnung L, et al
    Clinical efficacy and safety of high dose trivalent influenza vaccine in adults and immunosuppressed populations -a systematic review and meta-analysis.
    J Infect. 2021 Aug 20. pii: S0163-4453(21)00417.
    PubMed     Abstract available

  10. GODOY P, Garcia-Cenoz M, Rius C, Munoz-Almagro C, et al
    Effectiveness of maternal pertussis vaccination in protecting newborn: a matched case-control study: Maternal pertussis vaccination in protecting newborn.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00404.
    PubMed     Abstract available

  11. DOUXFILS J, Gillot C, Mullier F, Favresse J, et al
    Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00405.

  12. ALLEN N, Brady M, Martin AIC, Domegan L, et al
    Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00394.

  13. YAHI N, Chahinian H, Fantini J
    Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination ?
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00392.
    PubMed     Abstract available

  14. Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00388.

  15. GOBBI F, Buonfrate D, Silva R, Martini D, et al
    Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine: SARS-CoV-2 infection early after the first vaccine dose.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00390.

  16. Predominance of Delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021.
    J Infect. 2021 Aug 5. pii: S0163-4453(21)00387.

  17. UDDEN F, Runow E, Slotved HC, Fuursted K, et al
    Characterization of Streptococcus pneumoniae detected in clinical respiratory tract samples in southern Sweden 2 to 4 years after introduction of PCV13.
    J Infect. 2021;83:190-196.
    PubMed     Abstract available

    July 2021
  18. WANG H, Liu F, Cao Y, Zhang N, et al
    Epidemiological characteristics of Varicella before and after the implementation of two-dose vaccination schedule in Chaoyang District, Beijing, 2007-2019.
    J Infect. 2021 Jul 29. pii: S0163-4453(21)00378.

  19. BENE MC, Bittencourt MC, Chevallier P
    Post-SARS-CoV-2 vaccination specific antibody decrease : let's get the half-full glass perspective.
    J Infect. 2021 Jul 28. pii: S0163-4453(21)00370.

  20. EBANKS D, Faustini S, Shields A, Parry H, et al
    Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays.
    J Infect. 2021 Jul 26. pii: S0163-4453(21)00363.

  21. GIDARI A, Sabbatini S, Bastianelli S, Pierucci S, et al
    Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    J Infect. 2021 Jul 25. pii: S0163-4453(21)00362.
    PubMed     Abstract available

    Crossing the Rubicon: a Fine Line between Waiting and Vaccinating Adolescents against COVID-19.
    J Infect. 2021 Jul 21. pii: S0163-4453(21)00357.
    PubMed     Abstract available

  23. MOMBELLI M, Hoschler K, Cavassini M, Pascual M, et al
    Seasonal Trivalent Inactivated Influenza Vaccine with Topical Imiquimod in Immunocompromised Patients: a Randomized Controlled Trial.
    J Infect. 2021 Jul 20. pii: S0163-4453(21)00353.
    PubMed     Abstract available

  24. ANGELETTI S, Giovanetti M, Fogolari M, De Florio L, et al
    Detection of a SARS-CoV-2 P.1.1 variant lacking N501Y in a vaccinated Health Care worker in Italy.
    J Infect. 2021 Jul 5. pii: S0163-4453(21)00325.
    PubMed     Abstract available

  25. FAVRESSE J, Douxfils J
    Importance of Sample Dilution in the Evaluation of the Antibody Response after SARS-CoV-2 Vaccination.
    J Infect. 2021 Jul 4. pii: S0163-4453(21)00327.

    June 2021
  26. HSU L, Wisplinghoff H, Kossow A, Hurrass J, et al
    Limited protection against SARS-CoV-2 infection and virus transmission after mRNA vaccination.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00320.

  27. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00321.

  28. TRE-HARDY M, Cupaiolo R, Wilmet A, Beukinga I, et al
    Waning antibodies in SARS-CoV-2 naive vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
    J Infect. 2021 Jun 20. pii: S0163-4453(21)00314.

  29. DIMEGLIO C, Herin F, Miedouge M, Da-Silva I, et al
    One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.
    J Infect. 2021 Jun 17. pii: S0163-4453(21)00312.

  30. KWOK KO, McNeil EB, Tsoi MTF, Wei VWI, et al
    Will achieving herd immunity be a road to success to end the COVID-19 pandemic?
    J Infect. 2021 Jun 9. pii: S0163-4453(21)00287.
    PubMed     Abstract available

  31. AKPOLAT T, Uzun O
    J Infect. 2021 Jun 8. pii: S0163-4453(21)00285.

    May 2021
  32. RAW RK, Kelly C, Rees J, Wroe C, et al
    Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination.
    J Infect. 2021 May 29. pii: S0163-4453(21)00277.

  33. PEZZATI L, Giacomelli A, Mileto D, Conti F, et al
    Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: a cross-sectional study.: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine.
    J Infect. 2021 May 29. pii: S0163-4453(21)00271.

  34. BUTT AA, Khan T, Yan P, Shaikh OS, et al
    Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination.
    J Infect. 2021 May 28. pii: S0163-4453(21)00263.

  35. J BP, Jolly B, John N, Bhoyar RC, et al
    Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.
    J Infect. 2021 May 24. pii: S0163-4453(21)00260.

  36. WHITAKER HJ, Elgohari S, Rowe C, Otter AD, et al
    Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.
    J Infect. 2021 May 11. pii: S0163-4453(21)00224.
    PubMed     Abstract available

  37. SANSONE E, Tiraboschi M, Sala E, Albini E, et al
    Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
    J Infect. 2021 May 6. pii: S0163-4453(21)00225.
    PubMed     Abstract available

    April 2021
  38. GARVEY MI, Wilkinson MAC, Holden E, Shields A, et al
    Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00214.

  39. MARTINON-TORRES F, Banzhoff A, Azzari C, De Wals P, et al
    Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination: Real-world effectiveness of MenB vaccination.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00218.
    PubMed     Abstract available

  40. DONADIO C, Rainone A, Gouronnec A, Belmin J, et al
    Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: a case series in a geriatric rehabilitation ward during an outbreak.
    J Infect. 2021 Apr 11. pii: S0163-4453(21)00167.

  41. LODI L, Moriondo M, Nieddu F, Ricci S, et al
    Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period
    J Infect. 2021;82:28-36.
    PubMed     Abstract available

    February 2021
  42. ABAD R, Garcia-Amil C, Navarro C, Martin E, et al
    Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp).
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00087.
    PubMed     Abstract available

  43. BAO HL, Jin C, Wang S, Song Y, et al
    Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: A nationwide population-based study.
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00084.
    PubMed     Abstract available

  44. ANTONELLI M, Capdevila J, Chaudhari A, Granerod J, et al
    Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohort.
    J Infect. 2021 Feb 13. pii: S0163-4453(21)00079.
    PubMed     Abstract available

    December 2020
  45. ZENG H, Yi L, Chen X, Zhou H, et al
    First detection of EV-A71 genotype C1 in China Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China.
    J Infect. 2020 Dec 26. pii: S0163-4453(20)30782.
    PubMed     Abstract available

    November 2020
  46. LEVI M, Miglietta A, Romeo G, Bartolacci S, et al
    Letter in response to article in Journal of Infection: Impact of Routine Infant BCG Vaccination on COVID-19.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30718.

  47. HAMED E, Alnuaimi AS, Syed MA, Elhamid MA, et al
    Clinical characteristics of 51815 patients presenting with positive and negative SARS-CoV-2 swab results in primary health care settings.
    J Infect. 2020 Nov 13. pii: S0163-4453(20)30709.

  48. AYE AMM, Bai X, Borrow R, Bory S, et al
    Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative.
    J Infect. 2020;81:698-711.
    PubMed     Abstract available

    October 2020
  49. SUAYA JA, Mendes RE, Sings HL, Arguedas A, et al
    Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 20092017.
    J Infect. 2020;81:557-566.
    PubMed     Abstract available

  50. SMITH EL, Wheeler I, Adler H, Ferreira DM, et al
    Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors.
    J Infect. 2020;81:540-548.
    PubMed     Abstract available

    August 2020
  51. GLATMAN-FREEDMAN A, Kaufman Z, Applbaum Y, Dichtiar R, et al
    Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017.
    J Infect. 2020;81:297-303.
    PubMed     Abstract available

  52. GOMEZ-RIAL J, Rivero-Calle I, Salas A, Martinon-Torres F, et al
    Rotavirus and autoimmunity.
    J Infect. 2020;81:183-189.
    PubMed     Abstract available

    July 2020
  53. NYAZIKA TK, Law A, Swarthout TD, Sibale L, et al
    Influenza-like illness is associated with high pneumococcal carriage density in Malawian children.
    J Infect. 2020 Jul 22. pii: S0163-4453(20)30495.
    PubMed     Abstract available

    May 2020
  54. DEGHMANE AE, Haeghebaert S, Hong E, Jousset A, et al
    Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018.
    J Infect. 2020;80:519-526.
    PubMed     Abstract available

    March 2020
  55. BEEBEEJAUN K, Parikh SR, Campbell H, Gray S, et al
    Invasive meningococcal disease: Timing and cause of death in England, 2008-2015.
    J Infect. 2020;80:286-290.
    PubMed     Abstract available

    February 2020
  56. CAMPBELL H, Andrews N, Parikh S, Ribeiro S, et al
    Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England.
    J Infect. 2020;80:182-189.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.